Abbott Laboratories (ABT) Change in Receivables (2009 - 2026)

Abbott Laboratories has disclosed Change in Receivables across 18 years of filings, most recently posting $386.0 million for Q2 2026.

• In Q2 2026, Change in Receivables fell 5.85% year-over-year to $386.0 million; the TTM figure through Jun 2026 stood at $408.0 million (down 54.0% YoY), while the FY2025 annual figure was $652.0 million, down 5.64% from the prior year.
• Change in Receivables came in at $386.0 million for Q2 2026 at Abbott Laboratories, up from $42.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $751.0 million in Q1 2022 to a low of -$530.0 million in Q3 2022.
• Average Change in Receivables over 5 years is $121.9 million, with a median of $173.0 million recorded in 2022.
• The largest YoY upside for Change in Receivables was 637.14% in 2022 against a maximum downside of 280.42% in 2022.
• Over 5 years, Change in Receivables stood at -$341.0 million in 2022, then soared by 80.06% to -$68.0 million in 2023, then surged by 332.35% to $158.0 million in 2024, then tumbled by 240.51% to -$222.0 million in 2025, then soared by 273.87% to $386.0 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $386.0 million in Q2 2026, $42.0 million in Q1 2026, and -$222.0 million in Q4 2025.